 |
| India Immuno-Oncology Drugs Market |
The global India Immuno-Oncology Drugs Market is estimated to be valued at US$ 338.98 Mn or Mn in 2023 and is expected to exhibit a CAGR of 13.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Immuno-oncology drugs help boost the body's natural defenses to fight cancer.
These specialized biologics help trigger the patient's own immune system to
detect and destroy cancer cells more effectively. The rising prevalence of
cancer and limitations of conventional treatment methods are driving
significant demand for these new targeted therapies in India.
Market key trends:
The key trend fueling growth in the India immuno-oncology market is the
increasing adoption of combination therapies. Recent clinical trials have shown
that combining dissimilar immuno-oncology drug classes such as checkpoint
inhibitors and cancer vaccines works better than single-agent treatments. This
has prompted more oncologists to prescribe blended regimens. Furthermore,
rising healthcare expenditures and focus of global biopharma leaders to
introduce affordable biosimilars are expected to boost accessibility to these
life-saving drugs over the forecast period.
Segment Analysis
The India immuno-oncology drugs market is dominated by the monoclonal
antibodies segment. This is due to the increasing adoption of monoclonal
antibodies as a preferred treatment option for cancer indications like non-small
cell lung cancer, renal cell carcinoma, and metastatic melanoma. Monoclonal
antibodies function by increasing the immune system's ability to fight cancer
and by interfering with specific molecules involved in tumor growth and
progression.
Key Takeaways
The India
Immuno-Oncology Drugs Market Growth is expected to witness high growth,
exhibiting a CAGR of 13% over the
forecast period, due to increasing incidence of cancer in India.
Regional analysis
The Southern region of India dominates the immuno-oncology drugs market owing
to a higher number of patients undergoing cancer treatment in this region.
availability of modern healthcare infrastructure also contributes to its large
market share.
Key players
Key players operating in the India immuno-oncology drugs market are Amgen Inc.,
F. Hoffmann-La Roche AG., Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan
N.V., Dr. Reddy's Laboratories, Bristol - Myers Squibb, Merck & Co., Inc.,
BIOCAD-Biotechnology company, Reliance Life Sciences, Biocon Limited, and Hetero
Drugs Limited.
For more insights, read- https://www.ukwebwire.com/india-immuno-oncology-drugs-market-trends-size-and-share-analysis/
0 Comments